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A chemoproteomics-based drug discovery strategy
is presented that utilizes a highly parallel screening
platform, encompassing more than 1000 targets,
with a focused chemical library prior to target selec-
tion. This chemoproteomics-based process enables
a data-driven selection of both the biological target
and chemical hit after the screen is complete. The
methodology has been exemplified for the purine
binding proteome (proteins utilizing ATP, NAD,
FAD). Screening of an 8000 member library yielded
over 1500 unique protein-ligand interactions, which
included novel hits for the oncology target Hsp90.
The approach, which also provides broad target
selectivity information, was used to drive the identifi-
cation of a potent and orally active Hsp90 inhibitor,
SNX-5422, which is currently in phase 1 clinical
studies.
INTRODUCTION
The discovery of new medicines continues to challenge the
pharmaceutical industry (GAO Report, 2006). A central issue is
that the identification of new drug candidates via pharmaceutical
research is an extended linear effort. Although modern techno-
logical improvements have accelerated segments of the drug
discovery process, this linear pathway to discovery has remained
largely unchanged: target identification, biological assay devel-
opment, primary screening to identify chemical hits, hit-to-lead
exploration, lead optimization, secondary or selectivity screen-
ing, and finally candidate selection.
Chemoproteomics-based screening approaches, directed at
molecules which target purine binding proteins, have been
shown recently to be able to provide substantial binding informa-
tion with regards to both targets inhibited and relative binding
affinities. (Graves et al., 2002; Haystead, 2006; Duncan et al.,
2008). In particular, these methods utilize Sepharose resins
coupled with electrophoresis and mass spectrometry to eval-686 Chemistry & Biology 17, 686–694, July 30, 2010 ª2010 Elsevier Luate noncovalent binding interactions. Since both selectivity
and affinity information is obtained in a single experiment, paral-
lelization of two steps of the drug discovery process (primary and
secondary screening) is achieved. Selectivity information is of
significant value for the purine-binding proteome given that it
hasmany druggable targets but also a number of proteins whose
functional inhibition would be expected to be detrimental. The
purine proteome consists of 1500 proteins as defined by an
ability to utilize a purine cofactor, such as ATP, NAD, or FAD
(Uniprot, 2008).
We report here further development and extension of this
chemoproteomics-based approach. In particular, we apply it
a direct manner to drug discovery by utilizing it in conjunction
with a focused chemical library. Of significance is that the library
screening is done prior to target selection, and thus the drug
discovery steps of target identification, primary screening, and
secondary screening are conducted in parallel across multiple
targets. We describe the design and application of the method-
ology to the chaperone protein Hsp90 which is currently an
oncology target of high interest (Banerji, 2009). This effort has
led to the discovery of SNX-5422 as a highly selective, orally
activeHsp90 inhibitor for oncology that is in phase 1 clinical trials.
RESULTS
Screening Results
The first step in the approach used herewas creation of a suitable
chemical library. A 5000member focused compound library was
designed from commercially available compounds with the goal
of creating a maximally diverse compound set that was targeted
for any purine cofactor site across the proteome. Cheminfor-
matic approaches (see Experimental Procedures; see Supple-
mental Experimental Procedures available online) were used to
develop and refine descriptors that allowed preferential identifi-
cation of known purine protein binding compounds from a pool
of several million compounds. The computed fingerprints incor-
porated general features of themolecule (e.g., number hydrogen
bond donors and acceptors, number of rings) as well as specific
topological torsions and finally the presence or absence of char-
acteristic purine binding motifs. These descriptors were then
used to select uncharacterized compounds for screening. Thetd All rights reserved
Figure 1. Overview of Chemoproteomics-Based Discovery Process
(A) Schematic indicating that steps that are typically sequential in drug
discovery (yellow oval) are now accomplished in parallel fashion through use
of the screening methodology.
(B) Schematic of screening technique which is initiated by loading of a pro-
teome extract onto an optimized affinity chromatography resin. Subsequent
challenge with a compound will compete off the resin proteins with sufficient
binding affinity for that compound and these proteins can be identified via
mass spectrometry techniques.
Table 1. Summary Results from Chemical Library Screen







Initial (5000) 963 463 77
Follow-up (3000) 616 185 81
Total (8000) 1579 648 118
Cellular Assay Results
Library IC50 <1 mM IC50 <5 mM IC50 <10 mM
Initial (5000) 38 96 117
Follow-up (3000) 70 171 295
Total (8,000) 108 267 412
Target Affinity Screen Results
Protein Family Members Eluted
Actin/myosin related 5




Receptor tyrosine kinase 15
Nonreceptor tyrosine kinase 8
NAD oxidoreductase 17
Other miscellaneous classes 26
Total 118
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porcine lung or liver, evaluating each compound at a single
concentration with follow-up screening of selected compounds
at three concentrations as illustrated in Figure 1.
The breadth of the screening method was demonstrated by
the identification of proteins from a wide variety of enzyme
families, including both ATP-binding and NAD-binding enzymes.
Gene families represented included hydrolases, kinases, dehy-
drogenases, tranferases, carboxlyases, and chaperone pro-
teins. From the initial library of 5000 compounds, approximately
1000 unique compound-protein pairs were identified, which
comprised 463 compounds, eluting a total of 77 distinct proteins
(Table 1). Initial structure-activity relationships of the hits were
explored through the acquisition of a 3000 member follow-up
library that was selected based on chemical similarity to the
initial 463 hits. This latter library was screened in the same
manner generating about 600 compound-protein pairs (compa-
rable hit rate to the initial library). Of the 85 proteins eluted by the
185 follow-up compounds, 41 of the proteins were new and had
not been observed in the screen of the first 5000member collec-
tion. An additional effort was aimed at identifying, at an early
stage, compound-target interactions which might also demon-
strate cellular effects. In parallel, the library compounds were
screened for their ability to inhibit proliferation in three cell lines
(MCF-7, NCI-H460, HUVEC), with a total of about 250 com-
pounds displaying IC50 values of less than 5 mM.
Examples of the raw data generated from an unbiased screen
are illustrated in Figure 2. In Figure 2A, three compounds (1–3)
from distinct structural classes are compared for the proteins
they eluted. Compounds 1 and 2 were examples of compoundsChemistry & Biology 17,eluting a single target, pyridoxal kinase (PDXK) and 3-hydrox-
yacyl-CoA dehydrogenase (HCDH), respectively, with clean
binding profiles otherwise. Conversely, compound 3 clearly
showed a dual inhibition profile to proteins Hsp90 and S-adeno-
sylhomocysteine hydrolase (SAHH).
These examples were also selected to illustrate the range of
proteins that can be profiled. PDXK, HCDH, Hsp90, and SAHH
are from distinct protein families with diverse functions (Uniprot,
2008): PDXK is essential to vitamin B6 synthesis; HCDH is an
enzyme of beta fatty acid oxidation, and SAHH is involved in
methylation function and homocysteine metabolism. Addition-
ally, Hsp90 and PDXK utilize ATP whereas HCDH and SAHH
use NADH as a cofactor (Uniprot, 2008). Despite the inherent
complexity of screening hundreds of protein targets in parallel,
the method is also sufficiently sensitive to highlight target selec-
tivity differences between closely related compounds as shown
in Figure 2B. For example, purine 4 eluted alcohol dehydroge-
nase (ADH4) as well as modestly eluting Hsp90 family member
endoplasmin (GRP94) while minimal binding to Hsp90 isoforms
alpha and beta was observed. In contrast, the close analog 5
showed enhanced Hsp90 elution, diminished GRP94 elution,
and did not elute ADH4 but instead showed interaction with
SAHH. Quite remarkable is the difference observed between
two very closely related analogs of methotrexate; t-butyl analog
7 shows significant affinity for 2,4-dienoyl reductase (DECR)
whereas the olefin analog 6 does not elute this target but
displays a higher affinity for pyruvate carboxylase (PYC) and pro-
pionyl CoA-carboxylase (PCCA, PCCB). More generally, metho-
trexate and a range of analogs were found to show appreciable
binding (IC50’s <150 nM, data not shown) to biotin carboxylase686–694, July 30, 2010 ª2010 Elsevier Ltd All rights reserved 687
Figure 2. Screening a Targeted Library
For all gels, compound concentrations increase from left to right (20, 50, and
500 mM). Protein identifications: a = PDXK; b = HCDH; c = GRP94; d = HSP90
(a and b); e = SAHH; f = ADH4; g = PYC; h = PCCA; i = PCCB; j = DECR;
k = synapsin.
(A) Protein elution profiles of individual compounds from porcine lung.
Compounds 1 and 2 are representative of compounds that eluted one primary
target whereas compound 3 illustrates a dual inhibitor identified in the
screening process.
(B) Protein elution profiles of two closely related pairs of compounds from
porcine liver. Despite a high degree of similarity, compounds display a distinct
target elution profile.
(C) Example compounds that eluted Hsp90 (filled triangle) from affinity resin.
Yellow boxes indicate off-targets, which were a series of protein kinases for
compound 9 and ALDH2 for compound 12.
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therapeutic relevance.
Novel Hits for Hsp90
Of the compound-protein interactions identified in the initial
screen, several involved the chaperone protein Hsp90. Hsp90
has emerged as a promising drug target in as well as other
diseases involving mutant, foreign, or aberrantly expressed
proteins oncology (Whitesell and Lindquist, 2005; Chiosis
et al., 2004; Calderwood et al., 2006; Neckers, 2007; Solit and
Chiosis, 2008). The client proteins of Hsp90 include a wide range688 Chemistry & Biology 17, 686–694, July 30, 2010 ª2010 Elsevier Lof potentially oncogenic proteins, including Her2, c-Kit, and
mutated EGFR. Hsp90 is an ATPase and this activity is required
for it to maintain the proper folding of its client proteins
(Obermann et al., 1998; Panaretou et al., 1998; Pearl and Prodro-
mou, 2006; Pratt and Toft, 2003). Early work on inhibitors of
Hsp90 focused on natural product ansamycins and radicicol
(Whitesell et al., 1994; Sharma et al., 1998; Schulte et al., 1998;
Stebbins et al., 1997; Roe et al., 1999), as well as small molecule
purine and resorcinol-based scaffolds (Janin, 2005; Chiosis
and Tao, 2006; Powers and Workman, 2007; Kasibhatla et al.,
2007; Brough et al., 2008; Dymock et al., 2005; Vilenchik
et al., 2004). At the time of the screen, geldanamycin analogs,
17-AAG and 17-DMAG, had entered early clinical development;
however, due to a general lack of oral bioavailability of
17-AAG, as well as potential for chemical reactivity, identification
of novel small molecule inhibitors of Hsp90 would be highly
desirable.
The initial hits for Hsp90 identified by this screen possessed
structural novelty and diversity. Several hits are shown in
Figure 2C; only one of the six compounds shown, compound
13, contained an adenine substructure. The data for Hsp90
further illustrated the capability of the approach to provide
secondary screening information in addition and parallel to that
generated for the primary target of interest. In particular, purine
9 and quinazoline 12 both showed alternate protein elutions in
addition to Hsp90 with 9 eluting a series of protein kinases and
12 demonstrating moderate affinity interactions with aldehyde
dehydrogenase (ALDH2). Additional proteome mining using
porcine brain tissue also revealed that compound 13 was
observed to elute the protein Synapsin which regulates neuro-
transmitter release and has been shown to have an ATP binding
domain (Esser et al., 1998). It would likely be highly undesirable
to have off-target binding to this protein, and early identification
of this interaction helped inform the decision to not pursue opti-
mization of this particular scaffold. The ability of a focused library
of small size to still provide a breadth of distinct scaffolds was
demonstrated in that, subsequent to this work, publications
and patent applications have appeared that describe com-
pounds inhibiting Hsp90 that are closely related to, or in some
cases identical to, compounds 8, 9, 11, and 12 (Eggenweiler
and Wolf, 2006; Carrez et al., 2006; Machajewski et al., 2006;
Eggenweiler et al., 2006). This affinity-based screen also pro-
vided a unique advantage for the chaperone family; all four
isoforms of Hsp90, Hsp90a, Hsp90b, Grp94, and Trap1, could
be screened in a single assay.
Confirmation of ATP-Competitive Binding Mode
Based on both the combined attractiveness of Hsp90 as a target
for oncology and the chemical hits emerging from the screen,
Hsp90 was selected as a discovery program. In particular,
benzamide 10 was selected for optimization based on its
novelty, chemical tractability, and high degree of target selec-
tivity. Medicinal chemistry exploration of amide 10 led to
a number of initial analogs with increased affinity for Hsp90 while
maintaining a high degree of selectivity. Implicit in the screening
methodology, targeted at purine binding proteins, was the
assumption that protein-compound interactions identified
were due to competitive binding at the nucleotide binding site.
Prior to more extensive optimization efforts, X-raytd All rights reserved
Figure 3. X-ray structure of Cocrystal of HSP90a with Benzamide
Derivative 14, 2-(3,4,5-Trimethoxy-Phenylamino)-4-(2,6,6-Trimethyl-
4-Oxo-4,5,6,7-Tetrahydro-Indol-1-yl)-Benzamide
(A) Ribbon view of the entire crystallized N-terminal domain (residues 1–232)
with compound.
(B) Close-up view of the ATP binding site region of cocrystal showing binding
mode of compound 14. Key direct and indirect hydrogen bonds to Asp93,
Thr184, and structural waters (magenta) mirror those observed in the crystal
structure reported for ADP and ATP. Indolone binding site is formed by
displacement of Leu107 from position occupied in ADP/ATP structures.
Figure 4. Identification and In Vitro Pharmacology of SNX-2112
(A) Modifications of benzamide 10 leading to SNX-2112 and SNX-5422.
Progressive changes to the chemical structures are indicated in blue.
(B) Concentration dependent elution of Hsp90 with a 90 min incubation of
either 17-AAG or SNX-2112 and the protein-laden affinity resin. The IC50 for
SNX-2112 determined by this approach is 30 nM.
(C) IC50 values for SNX-2112 and 17-AAG in tumor cell proliferation and Hsp90
client assays in nanomolars.
(D) High content screens were used to evaluate effects following SNX-2112
treatment. Panels 1 and 2 are images of A375 cells and show loss of pS6
(red) and induction of Hsp70 (green) following 1 mM SNX-2112 treatment.
Panels 3 and 4 are images of AU565 cells and show loss of Her2 (red) and
pERK (green) following 10 mM treatment with SNX-2112. Images of pS6/
Hsp70 are 10x magnification collected using a Cellomics ArrayScan; a Becton
Dickinson Pathway 435 instrument was used to collect the Her2/pERK images
at 203 magnification.
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assumption and provide insights into strategies for optimization.
An N-terminal domain construct (residues 1-232) of Hsp90awas
readily cocrystallized with a derivative 14, 2-(3,4,5-trimethoxy-
phenylamino)-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-
1-yl)-benzamide, to yield a high quality structure with amaximum
resolution of 1.9 A˚ (Figure 3A). The structure of the complex
clearly demonstrated that binding to Hsp90 was targeted to
the ATP binding site (Obermann et al., 1998; Panaretou et al.,
1998; Prodromou et al., 1997), and this result confirmed the val-
idity of the purine proteome-based screening strategy. In partic-
ular, the benzamide moiety provided analogous interactions to
those observed for ATP or ADP with the amide oxygen and
NH2 groupmimicking adenine N1 and N6, respectively, by form-
ing both direct and water mediated hydrogen bonds to Thr184
and Asp93 (Figure 3B). Additional hydrogen bonding and hydro-
phobic interactions were observed between the trimethoxy
phenyl ring of compound 14 and Hsp90 residues Lys58,
Met98, and Leu107. The ketone oxygen of the indolone ring
also exhibited a well-formed hydrogen bond with the hydroxyl
of Tyr139. In addition to this hydrogen bond, multiple favorable
hydrophobic interactions were observed especially between
the gem-dimethyl-cyclohexanone moiety of 14 and a series of
hydrophobic residues (Met98, Leu103, Leu107, Phe138,
Val150, and Trp162). The binding site for this moiety was largely
formed by a conformational rearrangement that leads to Leu107
being displaced from its position occupiedwhen ATP is bound. A
similar rearrangement has been reported for purine-based inhib-
itors (Wright et al., 2004; Immormino et al., 2006). Met98 and
Leu107 also pack tightly against the benzamide and trimethoxy
phenyl components of compound 14.
Identification of a Clinical Candidate, SNX-5422
Despite the richness in chemical diversity, none of the initial
Hsp90 hits displayed activity in cell-based assays, regardless
of whether antiproliferative activity or direct client protein effects
were examined. However, the opportunistic pursuit of the readilyChemistry & Biology 17,tractable benzamide hit 10 allowed rapid progress as summa-
rized in Figure 4. Assisted by structural information, design
efforts led to compound 15 which showed potent binding to
Hsp90 and cellular activity. Modifications to eliminate the poten-
tial metabolic liability at the C2 position of the pyrrole moiety of
15 in turn gave rise to SNX-2112 which displayed strong
in vitro antiproliferative activity. SNX-2112 blocked the prolifera-
tion of all human tumor cells tested with IC50 values ranging
from 0.2 to 140 nM (Figure 4C). Importantly, this compound
exhibited comparable potencies in cell-based assays for client
protein effects to those observed for antiproliferative endpoints.
SNX-2112 inducedwell-establishedHsp90 client protein effects,
such as loss of Her2, abrogation of Akt and ERK signaling path-
ways (measured via pS6 and pERK levels), and induction of
Hsp70 levels with EC50 values ranging from 3 to 9 nM (Figures
4C and 4D). In addition, the potency of SNX-2112 exceeded686–694, July 30, 2010 ª2010 Elsevier Ltd All rights reserved 689
Figure 5. In Vivo Pharmacology of SNX-5422
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Chemoproteomics Discovery of an Hsp90 Inhibitorthat of 17-AAG in the vast majority of cell lines evaluated. The
time-dependent increase in affinity reported for 17-AAG (Gool-
jarsingh et al., 2006) was similarly observed for SNX-2112.
When evaluated using the purine-affinity media (Figure 4B), an
increase in incubation time (from 5 to 90 min) of SNX-2112
produced a 10-fold increase in apparent affinity; calculated
apparent Ki values for SNX-2112 binding were 22 and 1.5 nM,
respectively.
In order to improve kinetic solubility of the crystalline form of
SNX-2112, a glycine ester prodrug functionality was added,
yielding SNX-5422 (Figure 4A). Conversion of ester SNX-5422
to parent SNX-2112 was rapid and complete in vivo following
oral dosing (Figure 5A) and resulted in excellent exposure of
the parent compound. Parameters calculated (WinNonlin
software) for a single 30 mg/kg dose in female rats (n = 3) were
T1/2 = 6.0 hr; Tmax = 2 hr; Cmax = 2427 ng/ml; AUC0-inf =
19,232 hr*ng/ml; apparent volume of distribution = 13,600ml/kg;
apparent clearance = 1560 ml/hr/kg. SNX-5422 also displayed
significant antitumor activity in various human tumor xenograft
models in mice and, unlike other Hsp90 natural product inhibi-
tors and their analogs, was highly effective when dosed orally.
As illustrated in Figure 5B, administration (p.o. three times per
week) SNX-5422 to nude mice implanted with BT-474 xenograft
tumors resulted in regression of tumor growth. It is noteworthy
that only nine doses of SNX-5422, administered over the first
3 weeks resulted in six of nine mice being tumor free after
6 months. No overt adverse effects related to compound were
observed for the mice in the experiment. Coadministration of
SNX-5422 (low dose) with theHer2 antibody, trastuzumab (Vogel
et al., 2002), also resulted in tumor regression.
(A) EXPOSURE of SNX-2112 following oral dosing of SNX-5422 in female rats.
Data are from average of three animals with SEM shown. Levels of prodrug
were below the lower limit of quantitation (LLOQ) at all time points.
(B) Effects on BT-474 tumor-bearing nude mice (n = 10) dosed with vehicle or
(1) 10 mg/kg SNX-5422 (SNX) p.o. three times per week, (2) trastuzumab (TZB)
3 mg/kg i.v., two times per week, (3) 10 mg/kg SNX p.o. three times per week
and TZB 3 mg/kg i.v., two times per week, or (4) 40 mg/kg SNX three times per
week. Dosing in all drug-treated groups was for only the first 3 weeks. All
groups were followed for 6 months or until sacrifice due to tumor burden.DISCUSSION
The central step of the discovery methodology presented here is
a chemoproteomics-based screening process that can be
viewed as an extensively parallel competitive binding assay.
The affinity media (Hardeman et al., 2004) was optimized to
bind not only ATP-binding proteins, such as kinases, but also
proteins that utilize other purine cofactors such as NAD. Binding
of the proteins to the affinity resin is a fully reversible equilibrium
process and involves no covalent modification (Figure 1). Addi-
tionally, it can be performed in a standard 96-well format where
each well is challenged with a discreet compound. Both of these
factors make the approach favorable for incorporation within
a drug discovery framework. Specific tissues or cell types may
be evaluated and compared for binding to a compound. In
fact, typically a background gel pattern, characteristic of the
specific tissue or cell type expressed proteome, is observed
owing to the fact that binding of proteins to the resin is dynamic
and reversible. Since the eluant, excluding background, is
composed of only the proteins that possess affinity for the test
compound, the eluant profile is often quite simple. However,
theMSmethods used are capable of identifyingmultiple proteins
in the same gel band, with a practical limit of about four to five
proteins per band. Compounds that are selective ligands may
only elute a single protein where as promiscuous compounds,
e.g., staurosporine, may elute dozens of targets from the affinity
matrix.690 Chemistry & Biology 17, 686–694, July 30, 2010 ª2010 Elsevier LSeveral important distinctions between this approach and
traditional drug discovery are evident. First, the primary target
need not be selected in advance of the screen since each
compound is able to bind to any of the protein targets from the
tissue. In this sense, the process is one of self-selection since
the target is not selected without concomitant identification of
a hit compound. If a given compound is evaluated at multiple
concentrations, typically three concentrations in screening
mode, binding affinity data can be ascertained. Additionally,
broad target selectivity information is generated on each
compound as a necessary consequence of the screen design.
More informed follow-up of screening hits is thus enabled since
the method provides not only the affinity of the compounds for
a potential target of interest but also for a broad array of possible
off-targets. Use of this screening approach throughout hit-to-
lead and lead optimization provided ongoing target selectivity
information to guide medicinal chemistry efforts. Finally, native
protein is used for the screen, thereby obviating the often time-
consuming steps of cloning, expressing, and purifying the
protein in quantities sufficient for high-throughput screens.td All rights reserved
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validation. In the case study provided here, Hsp90 was clearly
already of interest in the scientific community with substantial
validation that preceded the work. Additionally, X-ray crystallog-
raphy, as described, was used to confirm the expected binding
mode to Hsp90, and this step too will always remain in the
discovery process. Nonetheless, there is no reason that the
approach could not be applied to a previously uncharacterized
biological target protein, and, as noted above, the advantages
of immediately having both a tool compound and information
on the selectivity profile of the compoundwould in principle facil-
itate validation of the target as one of interest.
The chemoproteomics approach utilized here can be
compared to alternative approaches directed at the purine
binding proteome. Use of reactive acyl phosphates has been
shown to allow detection of at least 75% of protein kinases
with good sensitivity to low abundance protein kinases (Patricelli
et al., 2007). This approach can also be used in a compound
screening mode. However, it differs from the method described
here in that a given compound must be determined to block
labeling of all proteins it inhibits within the context of the pro-
teome (i.e., absence of signal) versus this approach where one
is looking simply for a positive elution of proteins that are
inhibited (i.e., generation of signal). Use of bead bound inhibitors
as a chemoproteomics methodology has also been described
(Bantscheff et al., 2007). Again this approach has been shown
to have high sensitivity for detection and screening of com-
pounds versus protein kinases. It is dependent on having
known inhibitors to a target of interest and then using isobaric
tags for mass spectrometry-based quantification. Although
we have demonstrated the ability to detect a wide range of
protein kinases, low-copy proteins are one of the challenges
to this methodology, given that gel-based detection methods
are employed. Its strengths are the ability to profile a wide range
of purine binding protein family members with diverse protein
folds, especially metabolic proteins, and be utilized in a true
medium to high-throughput screening mode to evaluate chemi-
cal libraries.
Analysis of PFAMprotein fold data (Finn et al., 2008) for the hits
confirmed that the method can capture proteins from multiple
protein fold families, including targets of interest for pharmaceu-
tical intervention. For example, PDXK is a member of the pfkB
ribokinase family containing several carbohydrate and pyrimi-
dine kinases. Hsp90 is part of the HATPase_C group that
includes gyrase, histidine kinase, and the mismatch repair
protein mutL. PYC and PCCA/PCCB are both members of the
biotin carboxylase family that also includes the fatty acid enzyme
acetyl-CoA carboxylase which is currently metabolic drug target
of some interest (Harwood, 2004). Finally, HCDH and SAHH fall
into their own more distinct protein folds. SAHH has also
received substantial interest as a drug target particularly with
regards to its role in methylation and viral replication (Guillerm
et al., 2006). Thus, the diversity of enzyme classes (Table 1),
including both NAD and ATP binding proteins, and the range of
protein families exemplified as detectable by the methodology
support its ability to be utilized in a drug discovery mode for
targets within the purine binding proteome capture.
This chemoproteomics approach has been exemplified via
discovery of a clinical candidate targeting Hsp90. The screeningChemistry & Biology 17,methodology was used to identify compound-Hsp90 interac-
tions, prior to Hsp90 being selected as a target. Hits were prior-
itized in terms of both binding affinity and selectivity through
the methodology. In turn, these data facilitated rapid optimiza-
tion of the preferred scaffold to cell active, orally bioavailable
compounds. Based on its efficacy in multiple xenograft models,
with a variety of oral dosing schedules, SNX-5422 was selected
for clinical development and is currently in phase 1 trials in both
solid and hematological tumor patients.
SIGNIFICANCE
The chemoproteomics approach described here provides
a methodology by which a focused chemical library can be
profiled against a broad set of relevant targets. The resulting
data can then be analyzed to extract the best starting points,
with respect to both biology and chemistry, for subsequent
optimization. Because biological target choices are not
made a priori in advance of screening, but rather based on
the screening results, the mechanism is self-selecting.
There are numerous improvements to still be made to the
technology including improved sensitivity to low copy
proteins, better handling of membrane proteins, and poten-
tial migration to non-gel-based methods. Extension of the
method to other target classes, e.g., proteases and biogenic
amine receptors, is also of interest. Nonetheless, proof of
principle for the methodology has been demonstrated.
In particular, the ability to provide parallelization to certain
components of the discovery process has been shown
with the result that a clinical candidate was rapidly derived
from a small initial chemical library.
In conclusion, an unbiased affinity-based chemoproteo-
mics screen was used to profile an 8000 member targeted
library. This process self-selected Hsp90 as an attractive
drug discovery target based on the novelty and selectivity
of the screening hits. X-ray crystallography results con-
firmed that the proteome screen was functioning correctly.
Optimization of one scaffold, using Hsp90-specific cell-
based assays, led to the identification of SNX-2112 and
SNX-5422 as orally active Hsp90 inhibitors. SNX-5422 is
currently in phase 1 clinical trials in both solid and hemato-
logical tumor patients. This outcome validates the unique,
high-content discovery process and represents a successful




The general approach involved preparing a tissue lysate that was then incu-
bated with a purine-derived Sepharose affinity media (Hardeman et al.,
2004; example 29). Porcine tissues (40 g) were homogenized in buffer A
(120 ml) composed of 25 mM HEPES (pH 7.4), 60 mM NaCl, 20 mM MgCl2,
30 mM Na-b-glycerophosphate, 1 mM DTT, 1 mM Na-vanadate, and a
protease inhibitor cocktail. The homogenate was clarified by centrifugation
at 100,000 3g for 20 min and the resulting supernatant was decanted into
a 6 ml slurry (1:1) of the Sepharose affinity media in buffer A. The affinity media
was incubated with resin on ice for 45 min with gentle mixing. The proteome
loaded affinity media was transferred to a gravity feed column and washed
with 10 volumes of buffer A, followed by 20 volumes of buffer A plus
300 mM NaCl, and then 10 volumes of buffer B (25 mM HEPES [pH 7.4],686–694, July 30, 2010 ª2010 Elsevier Ltd All rights reserved 691
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Chemoproteomics Discovery of an Hsp90 Inhibitor120 mM NaCl, 20 mM MgCl2, 1 mM DTT, 1 mM Na-vanadate, and a protease
inhibitor cocktail). The loaded resin was transferred in equal amounts to 96
well, 200 ml filtertip pipette tip columns. Incubation of the test compound
with the protein-laden affinity matrix results in competitive binding for the
protein targets. Compound challenge was performed on a Tecan TeMo liquid
handler with compound in buffer B with 5% DMSO in a total volume of 75 ml.
A compound with sufficient affinity for a given protein inhibits its binding to the
affinity resin and the resulting compound-protein mixture was collected as the
column eluant. The complexity of the eluted proteins was visualized following
separation on a 1D SDS-PAGE gel with either Cypro ruby or silver staining.
Proteins that were visualized above background were identified using
standard trypsin gel band digest and MS/MS techniques (Rosenfeld et al.,
1992; Gharahdaghi et al., 1999). Gel band isolation, trypsin protease digest,
and mass spectrometry-based protein identifications were performed as
described previously (Chandarlapaty et al., 2008) using Applied Biosystems/
MDS SCIEX API 3000 or ABI 4700 MALDI TOF/TOF instrumentation. Apparent
Ki values for SNX-2112 were calculated using the equation Ki = IC50/(1+[S]/Kd)
where [S] = estimated purine resin concentration of 3mMand the Kd for Hsp90
is taken as 130 mM.
Focused Chemical Library Construction
The screening library was compiled from commercially available compound
collections. Vendor files in SDF file format were obtained from 19 vendors
and totaled approximately 2.4 million compounds. Algorithms (see below
and Supplemental Experimental Procedures) were developed in house to
profile each molecule based on its topology (bonds, dihedrals, rings, etc.)
and other molecule related characteristics or descriptors such as the number
of hydrogen bond donors and acceptors, hydrophobic moieties, and func-
tional groups occurrences. Once topology and descriptor information had
been generated, it was first used to filter molecules with undesirable properties
such as reactive species, having too many occurrences of certain functional
groups, or other general properties such as a high molecular weight. Eighty-
five filters were used (see Supplemental Experimental Procedures) with the
resulting elimination of approximately 50% of compounds.
The topology and descriptor information was then used to select
compounds sufficiently like a target adenosine analog. Initially, 40 known
purine target inhibitors (e.g., kinase inhibitors or methotrexate, see Supple-
mental Experimental Procedures) were profiled in the same manner as the
compounds under consideration. The information was summarized algorith-
mically as a ‘‘fingerprint’’ array. Elements of the fingerprint were weighted
such that when these test compounds were seeded into an otherwise random
collection of compounds, and their (Sørensen, 1948) coefficients were calcu-
lated relative to deoxyadenosine plus one benzene (for additional hydropho-
bicity), they would be preferentially selected from the collection. The profiles of
the compounds for purchasewere then converted to fingerprints andweighted
as with the test compounds. Again using Sørensen coefficients as similarity
criteria, a set on the order of 150K molecules was selected. Clustering based
on iterative maximal distance evaluation was then used to select 10K
compounds. Visual inspection by chemists reduced this set to the initial 5K
screening library.
More specifically, the cheminformatic characterization of given molecule
and similarity calculation between two molecules was as follows (see also
Supplemental Experimental Procedures). Each atom was assigned a core
functional type. For each regular or improper dihedral occurrence within
a molecule, excluding those containing hydrogens, the atoms in that dihedral
were converted to their functional types. Reference and test molecules were
then compared for their overlap of dihedrals via a Sørensen-type calculation,
and the calculated coefficient for this comparison was given a weighting factor
of 33.3. Additionally, each molecule was profiled for the total number of occur-
rences of various features such as functional types, rings, and the presence or
absence a purine binding motif (see Supplemental Experimental Procedures).
Forty-three total properties were assessed. These occurrences were option-
ally scaled and used to calculate a second Sorensen coefficient which was
given a weighting factor of 66.7. The two coefficients (topological torsions
and general properties) were combined to given a total similarity score with
0 indicating ‘‘identical’’ molecules in this system and 100 indicating maximal
dissimilarity. All characterization of molecules was done using in house soft-
ware programs written in C.692 Chemistry & Biology 17, 686–694, July 30, 2010 ª2010 Elsevier LX-ray Crystalllography
An N-terminal construct of human Hsp90a, residues 1–232, was used. Two- to
threefoldmolar excess of compound (as a 100mMDMSO stock) was added to
150 mM protein solution. Crystals were grown in 0.2 M MgCl2, 0.1 M Bis-Tris
(pH 6.5), and 20% PEG 3350 and were cryo-protected by adding 25%
ethylene glycol to the mother liquor and passing the crystal through the solu-
tion immediately before flash freezing it in liquid nitrogen. The crystals were
irregular shaped and measured approximately 300 3 200 3 100 mm and
grew up over approximately 2 days. A Rigaku FR-E+ SuperBright, rotating
anode, was used for data collection. Diffraction ambient temp was
113.15C. Summary data are shown below. The coordinates and structure
factor file will be deposited prior to publication.
Space Group: I222
Unit cell (A˚): a = 66.773, b = 90.753, c = 99.116, a = 90, b = 90, g = 90
Wavelength (A˚): 1.5418
Resolution (A˚): 36.45–1.90
No. of observations: 63297
No. of unique observations: 23,062
No. reflections, completeness (%): 21,887, 96
Redundancy: 2.74 (1.97–1.90 A˚, 1.8)
Completeness (%): 95 (1.97–1.90 A˚, 95)
I/s(I): 10.8 (1.97–1.90 A˚, 1.8)
R_sym: 0.084 (1.97–1.90 A˚, 0.130)
R_cryst, R_free (5% data): 0.188, 0.235
Rms bonds (A˚), rms angles (): 0.009, 1.30
Residues in allowed region of Ramachandran plot (%): 100
Cell Proliferation and Client Protein Measurements
All cell experiments were performed as previously described (Barta et al.,
2008) in 96-well assay plates. For proliferation assays, DNA from each treat-
ment condition was quantified using CyQuant fluorescent dye from Invitrogen
(Carlsbad, CA, USA). Levels of pS6/Hsp70 in A375 melanoma cells were
measured concurrently using the Compartmental analysis algorithm from
Cellomics (Pittsburg, PA). Individual cell nuclei were identified by Hoechst
staining; cytoplasm staining intensities were then determined for a four pixel
ring around the border of the identified nuclei. For each treatment condition,
data were collected for a minimum of 250 objects, and the average staining
intensity for each antibody was determined. For determining Her2/pERK in
AU565 cells, data were collected for 500 individual objects per treatment
condition, pERK intensity was determined for the nuclei area, and Her2 inten-
sity was determined for a circular area encompassing both the nuclei and an
additional four pixels into the cytoplasm.
Medicinal Chemistry
Methotrexate analogs 6 and 7 were synthesized as previously described
(Hanson et al., 2006). The syntheses of benzamide compounds 14 and 15,
as well as SNX-2112 and SNX-5422, have also been reported (Huang et al.,
2009).
Pharmacokinetics
In life work was conducted at Calvert Laboratories (Olyphant, PA). Female
Sprague-Dawley rats were 6–7 weeks old and weighed 130–265 g. Single
doses of SNX-5422 mesylate were administered by oral gavage to three
groups of nine animals, at 10, 20, and 30mg/kg. Blood samples were collected
from three rats at each time point: 0.5, 1, 2, 4, 6, 8, 12, and 24 hr after dosing.
Whole blood was collected from the retro-orbital sinus into chilled tubes con-
taining sodium heparin, and the blood was converted to plasma in a refriger-
ated centrifuge. The samples were stored frozen until LC-MS/MS analysis.
The concentrations of SNX-5422 and SNX-2112 in rat plasma were
determined by LC-MS/MS following protein precipitation with acetonitrile.
The calibration curve ranges were 1.40–5250 and 1.60–6000 ng/ml for SNX-
5422 and SNX-2112, respectively. The LC-MS/MS system consisted of
a Shimadzu Prominence HPLC (Shimadzu, Columbia, MD) coupled to a hybrid
triple quadrupole/linear ion trap mass spectrometer with a Turbospray source
(QTRAP, Applied Biosystems, Foster City, CA). The samples were injected
onto a Synergy Hydro-RP column, 2.0 3 30 mm, 4 mm (Phenomenex,td All rights reserved
Chemistry & Biology
Chemoproteomics Discovery of an Hsp90 InhibitorTorrance, CA), and the analytes and internal standardwere eluted at a flow rate
of 0.45 ml/min using a water-methanol gradient in the presence of 0.08–0.1%
formic acid and 4 mM ammonium formate. The ESI mass spectrometer was
operated in positive ion mode, using multiple reaction monitoring.
Mouse Xenografts
In life studies were performed at MIR (Michigan). SNX-5422 was suspended in
a 1%CMC (carboxlymethylcellulose) / 5% Tween 80 solution (pH 6.5). Trastu-
zumab was obtained from OTN as a dry, white lyophilized powder and was
stored in the dark at room temperature prior to being dissolved in sterile water
to give a pH 7.7 solution. Female athymic nu/nu mice were obtained from
Charles River. They were 7 weeks old on day 1 of the experiment. The animals
were fed irradiated Rodent Diet 5053 (LabDiet) andwater ad libitum. Micewere
housed in static cages with Bed-O’Cobs bedding inside Biobubble Clean
Rooms that provide H.E.P.A filtered air into the bubble environment at 100
complete air changes per hour. All treatments, body weight determinations,
and tumor measurements were carried out in the bubble environment. The
environmentwas controlled to a temperature range of 23 ± 2Cand a humidity
range of 30%–70%.
Test animals were implanted subcutaneously on day 0 with 30–60 mg
BT-474 tumor fragments using a 12 gauge trocar needle. All animals were
observed for clinical signs at least once daily. Animals with tumors in excess
of 1 g or with ulcerated tumors were euthanized, as were those found in
obvious distress or in a moribund condition. All procedures carried out in
this experiment were conducted in compliance with all the laws, regulations,
and guidelines of the National Institutes of Health (NIH) and with the approval
of MIR’s Animal Care and Use Committee. Treatments began on day 53, when
the mean estimated tumor mass for all groups in the experiment was 192 mg
(range, 179–207 mg). All animals weighed >19.5 g at the initiation of therapy.
Mean group body weights at first treatment were well matched (range, 22.7–
24.2 g). All animals were dosed according to individual body weight on the
day of treatment as indicated in the main text and Figure 5. Tumor measure-
ments were recorded twice weekly. Tumor burden (mg) was estimated from
caliper measurements by the formula for the volume of a prolate ellipsoid
assuming unit density as: tumor burden (mg) = (L 3 W2)/2, where L and W
are the respective orthogonal tumor length and width measurements (mm).ACCESSION NUMBERS
Coordinates for the HSP90-SNX1321 crystal structure have been deposited in
the RCSB protein data bank with accession code 3MNR.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
andcanbe foundwith this articleonlineat doi:10.1016/j.chembiol.2010.04.015.
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